Insulet (NASDAQ:PODD) Hits New 52-Week Low – Time to Sell?

Insulet Corporation (NASDAQ:PODD) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $146.20 and last traded at $148.1310, with a volume of 569929 shares changing hands. The stock had previously closed at $158.35.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Royal Bank Of Canada dropped their target price on Insulet from $325.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. The Goldman Sachs Group set a $237.00 price target on Insulet in a report on Thursday, May 7th. Wells Fargo & Company dropped their price target on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Finally, Leerink Partners lowered their target price on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Nineteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $257.09.

Insulet Stock Down 6.0%

The firm has a market capitalization of $10.31 billion, a price-to-earnings ratio of 34.61, a price-to-earnings-growth ratio of 1.25 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business has a fifty day moving average price of $205.63 and a two-hundred day moving average price of $260.20.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts expect that Insulet Corporation will post 6.44 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director directly owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PODD. Larson Financial Group LLC lifted its holdings in Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in Insulet in the fourth quarter valued at $26,000. DV Equities LLC purchased a new position in Insulet in the fourth quarter valued at $28,000. Elyxium Wealth LLC acquired a new position in shares of Insulet in the fourth quarter worth about $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in shares of Insulet during the 4th quarter worth about $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.